CPRX Earnings

CPRX reported its FY2025Q3 earnings on 2025-11-05, showcasing a revenue of 148.00M against an estimate of 137.00M, resulting in a 8.47% surprise. The EPS was 0.68, surpassing the expected 0.48 by 41.67% . The stock experienced a -1.82% price change on the earnings day and a 8.04% change over the next five days, reflecting market reactions to the results.

Following CPRX's FY2025Q3 earnings announcement on 2025-11-05, the stock price moved by -1.82% on the day of the release. Over the subsequent five days, it saw a 8.04% change. Historically, CPRX's stock price tends to shift by an average of +0.00% in the 10 days leading up to earnings and +3.91% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate CPRX’s annual revenue to reach 141.00M, while the EPS is projected at 0.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 2.81% and EPS estimates Revise Upward by 1.81% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between CPRX's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Upward by 2.81%, while EPS estimates moved Revise Upward by 1.81% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, CPRX's stock price typically moves by +0.00% in the 10 days before its earnings and +3.91% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 0.00 and revenue of 141.00M.

The earnings call summary indicates strong financial performance and reaffirmed guidance, suggesting stability. However, the Q&A reveals uncertainties, such as the lack of specifics on FYCOMPA's brand loyalty and AGAMREE's life cycle management, which could temper investor enthusiasm. The oncology portion of FIRDAPSE is more of a long-term story, and the impact of generics on FYCOMPA remains unclear. The market cap indicates a moderate reaction is likely, leading to a neutral stock price movement prediction.